Search Results
Improving CAR-T cell therapy outcomes for patients with for aggressive lymphoma and multiple myeloma
Despite the promise of CAR-T cell immunotherapy for patients with lymphoma and multiple myeloma, a significant proportion of patients fail to respond or relapse following treatment. This project will focus on the clinical translation of a new treatment designed to improve durable response rates by combining CAR-T cell therapy with a new class of anticancer drugs called SMAC-mimetics. The results will provide the evidence base to drive a first-in-human clinical trial of this combination strategy.
Clinical Trials: Why They Matter and How to Make Them More Accessible
Cancer treatments can be lifesaving. As an organization, The Leukemia & Lymphoma Society (LLS) has invested more than $1.7 billion in blood cancer research since its inception in 1949—all with the hope that this research leads to scientific breakthroughs that improve and save lives.
But to make sure this research leads to safe and innovative treatments, we have to thoroughly test it.
Pembrolizumab
Pembrolizumab is FDA approved for the treatment of
Enhancing efficacy of cyclin-dependent kinase inhibitors in diffuse large B-cell lymphoma
Nearly half of patients with diffuse large B-cell lymphoma (DLBCL), ultimately fail current therapies and die from their disease. Selective targeting of cyclin-dependent kinase 9 (CDK9) is a promising strategy, as evidenced by potent anti-tumor effects in preclinical models of DLBCL. Yet tumors evade therapy by developing resistance. This proposal seeks to both elucidate and circumvent the oncogenic events underlying this resistance in order to offer novel therapeutic approaches to treat DLBCL.HIGH SCHOOL STUDENTS 'TEST' THE LIMITS OF PHILANTHROPY
For the second year in a row, high school students across the country are redefining what it means to be philanthropic in today’s youth culture. Through The Leukemia & Lymphoma Society’s (LLS) newest innovation in fundraising, Students of the Year, more than 600 motivated high school students raised significant funds for LLS’s cutting-edge cancer research and patient services.
What’s Next in Blood Cancer: Looking Ahead to 2023
The most important blood cancer scientific meeting, the American Society of Hematology (ASH), is held every December.
Ibrutinib
Ibrutinib has been FDA-approved to treat:
- Patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
- Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (SLL) with 17p deletion.
- Patients with Waldenström macroglobulinemia (WM).
- Adult and pediatric patients age 1 year and older with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.
Obinutuzumab
Obinutuzumab is FDA-approved
Pirtobrutinib
Pirtobrutinib is indicated for the treatment of
Helping Blood Cancer Patients and Caregivers Navigate the Financial Impact of COVID-19
The coronavirus (COVID-19) pandemic has been a challenging time for us all. It is especially so for cancer patients and survivors, who are at greater risk of getting sicker if they become infected with the virus because they might be immunocompromised.
#ASH18: Update on Immunotherapy
Immunotherapy – harnessing the body’s immune system to fight disease – is rapidly becoming a mainstay of cancer treatment. The increasing interest in this field was clear at yesterday’s standing-room only symposium hosted by The Leukemia & Lymphoma Society in advance of the 60th ASH (American Society of Hematology) Meeting which officially kicks off today here in San Diego. Over the next few days more than 30,000 researchers and others connected to the blood cancers and other blood malignancies will gather to hear the latest data from clinical trials.
Defining and Redefining a Blood Cancer Diagnosis
Science historian June Goodfield wrote, “Cancer begins and ends with people.”
This Blood Cancer Awareness Month, it’s important to know that The Leukemia & Lymphoma Society (LLS) is on a mission to cure blood cancers and improve quality of life for the nearly 1.7 million people in the U.S. living with or in remission from blood cancer.
LLS is all about people—an organization full of people who are united in the urgent effort to help every person impacted by blood cancer.
Cyclophosphamide
Cyclophosphamide is FDA approved to treat several types of cancer, including people who have Hodgkin lymphoma, non-Hodgkin lymphoma, acute and chronic lymphocytic leukemia, acute and chronic myeloid leukemia, myeloma, and mycosis fungoides. Cyclophosphamide is usually used in combination with other drugs.
Cyclophosphamide may cause a temporary loss of hair in some people. After treatment has ended, normal hair growth should return, although the new hair may be a slightly different color or texture.
Researchers Share Key Career Advice with LLS College Club Members
I recently had the privilege of moderating an LLS on Campus Researcher Panel attended by LLS college club members from nearly 30 universities across the country. These clubs bring together students interested in pursuing health-related careers and provide opportunities to hear from scientists working to better understand and treat blood cancers.
Characterization and Targeting of Tumor-Associated Monocytes/ Macrophages that Limit the Efficacy of PD-1 Blockade in Lymphoma
Inhibition of the PD-1 exhaustion pathway enables the immune system to attack cancers. PD-1 blockade is now a standard treatment for relapsed classic Hodgkin Lymphoma (cHL) and a component of experimental frontline therapy. In patients with cHL, a newly identified population of monocytes/macrophages limits the efficacy of PD-1 blockade. We will characterize and target these tumor-programmed monocytes/macrophages for therapeutic benefit in patients with cHL and other lymphoid malignancies.Dacarbazine
Dacarbazine is used to treat people who have Hodgkin lymphoma as a second-line therapy when used in combination with other agents and is also used as initial therapy for some patients with Hodgkin lymphoma. It may cause a temporary loss of hair in some people. After treatment with dacarbazine has ended, normal hair growth should return.
Selinexor
Selinexor is FDA approved